Histiocitosis de células de Langerhans

  • Ana Milena Toro
  • Rodrigo Restrepo
  • Amparo Ochoa
Palabras clave: granuloma eosinófilo, manifestaciones cutáneas, Histiocitosis, células de Langerhans

Resumen

La histiocitosis de células de Langerhans es una proliferación clonal anormal de células con un inmunofenotipo positivo para S-100, CD1a y presencia de gránulos de Birbeck en el citoplasma. Se caracteriza por manifestaciones clínicas variables desde una enfermedad multisistémica aguda con alta mortalidad hasta una forma crónica de curso más benigno.
Se presenta una revisión sobre la fisiopatología, hallazgos clínicos y algunos conceptos importantes acerca del diagnóstico y tratamiento de las histiocitosis.

Biografía del autor/a

Ana Milena Toro

Dermatóloga. Universidad Pontificia Bolivariana. UPB.

Rodrigo Restrepo

Patólogo. Instructor asociado de patología y dermatopatología. UPB

Amparo Ochoa

Dermatóloga y docente de dermatología pediátrica. Universidad de Antioquia.

Citas

1. Goodman WT, Barrett TL. Histiocytoses. En: Bolognia JL, Jorizzo JL, Rapini RP (eds) Dermatology 2ª Edición. Elsevier, España 2007. p 1395 -400.
2. Caputo R, Gelmetti C. Langerhans Cell Histiocytosis. En: Freedberg IM, Eisen AZ, Wolff K et al (eds) Fitzpatrick´s Dermatology in General Medicine 7 ed. Mc Graw Hill 2007; p 1414 - 24.
3. Chu AC. Histiocytoses. In: Burns T, Breathnach S, Cox N, Griffiths C. Rook´s Textbook of Dermatology 7 ed. Blackwell Science 2004; vol 3 p: 52.1 – 52.33.
4. Favara BE, Feller AC, Pauli M, Jaffe ES, Weiss LM, Arico M, et al. Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol. 1997;29 :157- 66.
5. The structure and function of skin. In: Mckee PH, Calonje E, Granter SR. Pathology of the skin with clinical correlations. 3 Ed. Elsevier Mosby. 2005 p 16 – 8.
6. Histiocytic disorders. In: Mckee PH, Calonje E, Granter SR. Pathology of the skin with clinical correlations. 3 Ed. Elsevier Mosby. 2005 p 1457 – 84.
7. Writing Group of the Histiocyte Society. Histiocytosis syndromes in children. Lancet 1987; 1: 208–9.
8. Histiocytic and Dendritic Cell Neoplasms. In: Jaffe ES, Harris NL, Stein H, Vardimen JW (Eds.): World Health Organization Classification of tumors. Pathology and Genentics of Tumors of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon 2001.p: 273 - 89.
9. Coppes-Zantinga A, Egeler RM. Historical review the Langerhans cell histiocytosis x files revealed. Br J Haematol 2002; 116: 3 – 9.
10. Cambazard F, Stephan JL. The histiocytoses, Langerhans cell and non-Langerhans cell histiocytosis. In: Harper J, Orange A, Prose N (Eds). Textbook of pediatric dermatology 2 ed. Blackwell Science 2006; vol 2 p: 1699 – 721.
11. Willman CL, Busque L, Griffith BB, McClain KL, Duncan MH, Gilliland DG. Langerhans’ cell histiocytosis (histiocytosis X) a clonal proliferative disease. N Engl J Med 1994; 331:154-60.
12. Willman CH, McClain KL. An update on clonality, cytokines, and viral etiology in Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998; 12: 407 – 16.
13. McClain KL, Natkunam Y, Swerdlow SH. Atypical Cellular Disorders. Hematology Am Soc Hematol Educ Program. 2004; 283-96.
14. Nezelof C, Basset F. An Hipótesis Langerhans Cell Hisitiocytosis: The failure of the immune system to switch from an innate to an adaptive mode. Pediatr Blood Cancer 2004; 42:398 – 400.
15. Laman JD, Leenen PJ, Annels NE, Hogendorn P, Egeler RM. Langerhans-cell histiocytosis “insight into DC biology”. Trends Immunol 2003; 24: 190 – 6.
16. Fadeel B, Henter J. Langerhans-cell Histiocitosis: neoplasia or unbridled inflammation?. Trends Immunol 2003; 24: 409– 10.
17. Chu T. Langerhans cell histiocytosis. Australas J Dermatol 2001; 42: 237– 42.
18. Geissmann F, Lepelletier Y, Fraitag S, Valladeau J, Bodemer C, Debre M, et al. Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood 2001; 97: 1241 – 8.
19. Aricoa M, Nichols K, Whitlock JA, Arceci R, Haupt R, Mittler U. Familial clustering of Langerhans cell histiocytosis. Br J Haematol 1999; 107: 883- 8.
20. Broadbent V, Pritchard J, Davies EG, Levinsky RJ, Atherton. DJ, Heaf D, et al. Spontaneous remission of multi-system. histiocytosis X. Lancet 1984;1:253–4.
21. McClain k, Weiss R. Viruses and Langerhans cell Histiocytosis: is there a link? Br J Cancer 1994; 70: S34- S36.
22. Nicholson HS, Egeler RM, Nesbit ME. The epidemiology of Langerhans cell Histiocytosis. Hematol Oncol Clin North Am 1998;12: 379 – 84.
23. Egeler RM, Neglia JP, Arico M, Favara BE, Heitger A, Nesbit ME, et al. The relation of Langerhans cell histiocytosis to acute leukemia, lymphomas, and other solid tumors. The LchMalignancy Study Group Of The Histiocyte Society. Hematol Oncol Clin North Am 1998;12: 369 – 78.
24. Munn S, Chu AC. Langerhans cell histiocytosis of the skin. Hematol Oncol Clin North Am 1998;12: 269 – 86.
25. Jain S, Sehgal VN, Bajaj P. Nail Changes in Langerhans cell histiocytosis. JEADV 2000; 14: 212 – 5.
26. Arico M, Egeler RM, Clinical aspects of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998; 12: 247 – 58.
27. Meyer JS, Camargo B. The role of radiology in the diagnosis and follow- up of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998; 12: 307 – 26.
28. Grois N, Pötschger U, Prosch H, Minkov M, Arico M, Braier J, et al. Risk factors for diabetes insipidus in Langerhans cell histiocytosis. Pediatr Blood Cancer 2006; 46: 228 – 33.
29. Zelger B, Rapini RP, Burgdorf W, Burg G. Langerhans cell histiocytosis. In: LeBoit PE, Burg G, Weedon D, Sarasain A (Eds.): World Health Organization Classification of tumors. Pathology and Genetics of Skin Tumors. IARC Press: Lyon 2006. p: 217 – 9.
30. Newman B, Hu W, Nigro K, Gillian AC. Aggresive histiocytic disorders that can involve the skin. J Am Acad Dermatol 2007; 56: 302- 16.
31. Longaker MA, Frieden IJ, LeBoit PE, Sherertz EF. Congenital “self- healing” Langerhans cell histiocytosis: the need for long-term follow-up. J Am Acad Dermatol 1994; 31: 910- 6.
32. Hoeger PH, Janka-Schaub G, Mensing H. Late manifestation of diabetes insipidus in “pure” cutaneous cell histiocytosis. Eur J Pediatr 1997; 156: 524 – 7.
33. Ariza SA, Cardona AF, Rueda X. Histiocitiosis de células de Langerhans. Diez años de experiencia en el Instituto Nacional de Cancerología. Rev Asoc Col Dermatol. 2008; 16: 178 – 84.
34. Writing Group of the Histiocyte Society. Histiocytosis syndromes in children: II. Approach to the clinical and laboratory evaluation of children with Langerhans Cell Histiocytosis. Med Ped Oncol 1989 ;17:492 - 5.
35. Chu T. Langerhans cell histiocytosis. Australas J Dermatol. 2001; 42: 237 – 42.
36. Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr 2001; 138: 728 – 34.
37. Broadbent V, Gadner H. Current therapy for Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1998; 12: 327– 38.
38. Chu A. Langerhans cell histiocytosis. En: Lebwohl MG, Heymann WR, Berth-Jones J, Coulson L. Treatment of skin disease comprehensive therapeutic strategies 2ed. Elsevier Mosby. 2006 p. 324 – 7.
39. Sheehan MP, Atherton DJ, Broadbent V, Pritchard J. Topical nitrogen mustard: an effective treatment for cutaneous Langerhans cell histiocytosis. J Pedriatr. 1991; 119: 317 – 21.
40. Hoeger PH, Nanduri VR, Harper JI, Atherton D, Pritchard J. Long term follow up of topical mustine treatment for cutaneous Langerhans cell histiocytosis. Arch Dis Child 2000; 82: 483 - 7.
41. Thomas L, Ducros B, Secchi T, Balme B, Moulin G. Successful treatment of adults Langerhans cell histiocytosis with thalidomide. Arch Dermatol. 1993;129: 1261 - 4.
42. Sander CS, Kaatz M, Elsner P. Successful treatment of cutaneous langerhans cell histiocytosis with thalidomide. Dermatology. 2004; 208:149-52.
43. Tsambaos D, Georgiou S, Kapranos N, Monastirli A, Stratigos A, Berger H. Langerhans cell histiocytosis: complete remission after oral isotretinoin therapy. Acta Derm Venereol; 1995; 75: 62 – 4.
44. Gadner H, Grois N, Arico M, Broadbent V, Ceci A, Jakobson A, et al. A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr 2001; 138: 728 – 34.
45. Broadbent V, Gadner H. Current therapy for Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998; 12: 327– 38.
46. Chu A. Langerhans cell histiocytosis. En: Lebwohl MG, Heymann WR, Berth-Jones J, Coulson L. Treatment of skin disease comprehensive therapeutic strategies 2ed. Elsevier Mosby. 2006 p. 324 – 7.
47. Sheehan MP, Atherton DJ, Broadbent V, Pritchard J. Topical nitrogen mustard: an effective treatment for cutaneous Langerhans cell histiocytosis. J Pedriatr. 1991; 119: 317 – 21.
48. Hoeger PH, Nanduri VR, Harper JI, Atherton D, Pritchard J. Long term follow up of topical mustine treatment for cutaneous Langerhans cell histiocytosis. Arch Dis Child. 2000; 82: 483 - 7.
49. Thomas L, Ducros B, Secchi T, Balme B, Moulin G. Successful treatment of adults Langerhans cell histiocytosis with thalidomide. Arch Dermatol. 1993;129: 1261 - 4.
50. Sander CS, Kaatz M, Elsner P. Successful treatment of cutaneous langerhans cell histiocytosis with thalidomide. Dermatology. 2004;208: 149 - 52.
51. Tsambaos D, Georgiou S, Kapranos N, Monastirli A, Stratigos A, Berger H. Langerhans cell histiocytosis: complete remission after oral isotretinoin therapy. Acta Derm Venereol. 1995; 75: 62 - 4.
Cómo citar
1.
Toro AM, Restrepo R, Ochoa A. Histiocitosis de células de Langerhans. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 12 de febrero de 2019 [citado 20 de mayo de 2022];17(1):34-. Disponible en: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/148

Descargas

La descarga de datos todavía no está disponible.
Publicado
2019-02-12
Sección
Artículo de revisión

Artículos más leídos del mismo autor/a

1 2 3 4 5 > >>